Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinsons Disease
| SHPCX Fund | USD 13.90 0.03 0.22% |
Slightly above 55% of Health Biotchnology's investor base is interested to short. The analysis of overall sentiment of trading Health Biotchnology Portfolio mutual fund suggests that many investors are impartial at this time. Health Biotchnology's investing sentiment can be driven by a variety of factors including economic data, Health Biotchnology's earnings reports, geopolitical events, and overall market trends.
Health |
Neuron23 unveiled details around its global Phase 2 NEULARK clinical trial of NEU-411 in people with early Parkinsons disease.
Read at businesswire.com
 |
Health Biotchnology Fundamental Analysis
We analyze Health Biotchnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Health Biotchnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Health Biotchnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Health Biotchnology is currently under evaluation in price to sales among similar funds. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Health Biotchnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Health Biotchnology mutual fund to make a market-neutral strategy. Peer analysis of Health Biotchnology could also be used in its relative valuation, which is a method of valuing Health Biotchnology by comparing valuation metrics with similar companies.
Peers
Health Biotchnology Related Equities
| VOLMX | Volumetric Fund | 0.34 | ||||
| TQAAX | T Rowe | 0.32 | ||||
| CPUCX | Aam Select | 0.32 | ||||
| WRLDX | Scharf Global | 0.24 | ||||
| ABVCX | Ab Value | 0.1 | ||||
| TWBIX | Balanced Fund | 0.1 |
Other Information on Investing in Health Mutual Fund
Health Biotchnology financial ratios help investors to determine whether Health Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Health with respect to the benefits of owning Health Biotchnology security.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |